Annovis Bio, Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/2c3081b3-9abf-4b34-9c3b-6f505c097e4c/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-29.7M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-027751 |
| FY 2024 | $-26.7M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-003482 |
| FY 2023 | $-45.0M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-004393 |
| FY 2022 | $-25.5M | 2022-01-01 – 2022-12-31 | evidence 0001104659-23-040275 |
| FY 2021 | $-14.5M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002668 |
| FY 2020 | $-6.6M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002303 |
| FY 2019 | $-1.6M | 2019-01-01 – 2019-12-31 | evidence 0001558370-21-002303 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).